PITPNM3 is a CCL18 receptor, but PITPNM3 is only expressed on breast cancer cells and not on T-cells nor B-cells, and PITPNM3-CCL8 binding induces Pyk2 and Src mediated signaling, a cancer related signaling pathway, and subsequent metastasis of breast cancer.
PITPNM3 acts as a receptor for CCL18, but it is predominantly found on breast cancer cells rather than T-cells or B-cells. The interaction between PITPNM3 and CCL8 activates Pyk2 and Src signaling pathways, which are associated with the progression of breast cancer.